Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients
Status:
Recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
Triple-negative breast cancer (TNBC) refers to any breast cancer that does not express
estrogen receptor (ER), progesterone receptor (PR) or Her2/neu. Its incidence is
approximately 180,000 cases per year. TNBC are known to be more aggressive with poor
prognosis specially when no pathologic complete response (pCR) is achieved after neoadjuvant
chemotherapy, with a higher risk of recurrence and a poor survival once that recurrence
occurs. On the other hand, there is not a specific adjuvant or neoadjuvant treatment for
these patients. Since autologous hematopoietic stem cell transplantation (HSCT) allows the
usage of higher doses of chemotherapy, which results in higher cellular destruction with a
decrease of hematological toxicity, it is proposed that this procedure is able to improve
prognosis in TNBC patients with no pathologic complete response after neoadjuvant
chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran